RAPP-ID

Research Areas

- Tool Development
- Product Development
- Device

At a Glance

- Status: Active Consortium
- Year Launched: 2011
- Initiating Organization: Innovative Medicines Initiative
- Initiator Type: Government
- Location: Europe

Abstract

The development of rapid point-of-care test platforms for infectious diseases (RAPP-ID) consortium is an effort of the European Innovative Medicines Initiative that aims to provide an integrated solution that is capable of detecting multiple indicators of infectious diseases through a point-of-care diagnostic. The goal of the consortium is to address the technological challenges in bioengineering and integrate these solutions to enhance clinical decision-making and improve the quality of care and clinical outcomes.

Mission

The RAPP-ID consortium is focused on developing a point-of-care test (POCT) for rapid detection of bacteria, mycobacteria, and fungi, as well as viruses and host biomarkers by combining novel-specific probes, novel methods of sample preparation, and demonstrated ultra-high sensitive detection methods in hospital patients in fewer than two hours and for outpatients in fewer than 30 minutes. The platforms will also determine resistance to antimicrobial drugs.

The research will focus on pathogens and host biomarkers involved in:
Consortium History

2011 – Project start date (January)
2011 – RAPP-ID Kick-off meeting, UK (April)
2011 – Workshop 1, Belgium (July)
2011 – Workshop 2, Rome (November)
2012 – Workshop 3, Barcelona (January)
2012 – First annual meeting, Stockholm (May)

Structure & Governance

Management of the consortium is through a dedicated Project Coordination & Management Board, which provides the administrative and financial oversight, while the Governing Board and Steering Committee are responsible for ensuring the project achieves the consortium’s objectives in a timely manner.

Composition of the Project Coordination & Management Board:

The Project Coordinator: Dr. Jorge Villacian, JNJ
The Academic Coordinator: Prof Herman Goossens, UA
The Deputy Coordinator: Dr Linda Miller, GSK
The Project Manager: Dr Pieter Moons, UA
The Project Administrator: Anne Struyven, UA

Meeting frequency:
The Management and Coordination Board will meet face-to-face or by teleconference (TC) at least every two weeks.

Financing

This project is funded by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations.
(EFPIA), resources of which are composed of a financial contribution from the EU Seventh Framework Programme and EFPIA companies' in-kind contribution. Large pharmaceutical companies participating in IMI projects do not receive IMI funding.

<table>
<thead>
<tr>
<th>Contributions</th>
<th>€</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMI funding</td>
<td>6 828 438</td>
</tr>
<tr>
<td>EFPIA in-kind</td>
<td>5 848 470</td>
</tr>
<tr>
<td>Other</td>
<td>1 771 853</td>
</tr>
<tr>
<td>Total cost</td>
<td>14 448 761</td>
</tr>
</tbody>
</table>

**Intellectual Property**

The IMI Intellectual Property (IP) Policy governs the IP regime of all projects funded by the IMI JU. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk that can be contacted by e-mailing IMI-IP-Helpdesk@imi.europa.eu. The IMI IP policy can be accessed at the following address: [http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf](http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf)

**Data Sharing**

According to IMI’s intellectual property policy, the participants undertake to disseminate the data as soon as reasonably practicable but not later than one year after the termination or expiry of the project. The Project Agreement shall include a description of the material that must be disseminated in accordance with the IP Policy and referenced in the Grant Agreement. If the participants do not disseminate within such time periods without good reason, the Executive Office has the right to disseminate such results in a manner consistent with the Grant Agreement.

RAPP-ID aims to provide an integrated solution that addresses the technological challenges to enhance clinical decision-making and improve the quality of care and clinical outcomes for the people of Europe and worldwide.


Other website: [http://www.imi.europa.eu/content/rapp-id](http://www.imi.europa.eu/content/rapp-id)
Points of Contact

Jorge Villacian
Janssen Research & Development
Turnhoutseweg 30
Beerse
Belgium
jvillaci@its.jnj.com

Herman Goossens
Vaccine & Infectious Disease Institute
Universiteitsplein 1
2610 Wilrijk
Belgium
+32 3 821 37 89
herman.goossens@uza.be

Pieter Moons
Vaccine & Infectious Disease Institute
Universiteitsplein 1 - S.621
2610 Wilrijk
Belgium
+32 3 265 25 43
pieter.moons@uantwerpen.be

Anne Struyven
Vaccine & Infectious Disease Institute
Universiteitsplein 1 - S.620
2610 Wilrijk
Belgium
+32 3 265 21 58
anne.struyven@uantwerpen.be

Sponsors & Partners
GlaxoSmithKline Research and Development LTD, UK
Johnson & Johnson - Tibotec-Virco Virology, Belgium
Merck, USA
Novartis Vaccines and Diagnostics Srl, Italy
Sanofi-Aventis Research and Development, France
University of Cardiff, UK
IMEC, Belgium
KUL - Catholic University of Leuven, Belgium
KTH – Royal Institute of Technology, Sweden
University of Cambridge, UK
University of Geneva, Switzerland
University of Antwerp, Belgium
University of Gent, PBM Group, Belgium
University of Twente, Netherlands
University of Uppsala, Sweden
LIONEX, Germany
microfluidic ChipShop, Germany
Mobidiag Ltd, Finland
Q-linea, Sweden

Updated: 04/08/2016